ArticleFrontiers in immunology2019
NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- High-Dimensional Immune Profiling Identifies Circulating NKT-Like Cells Associated With Severity Outcome in Acute Pancreatitis at Disease Onset.Immunology · 2026Article
- Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4Cell reports. Medicine · 2026Article
- Age-Matched Reference Values for Circulating Natural Killer T (NKT)-Like Cells.Scandinavian journal of immunology · 2025Article
- NKT cells-a generalist in disease treatment and a new key to unlock immunotherapy.Immunotherapy · 2025Review
- AI-assisted peripheral immune profiling reveals unconventional lymphocyte signatures associated with prognosis in soft tissue sarcoma patients.Frontiers in immunology · 2025Article
- Immune checkpoints PD1/PDL1, TIM3/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia.Annals of hematology · 2024Article
- Immune Profile in COVID-19: Unveiling TInternational journal of molecular sciences · 2024Article
- Article
- Thymic NK-Cells and Their Potential in Cancer Immunotherapy.ImmunoTargets and therapy · 2024Review
- Regulatory TCells · 2023Review
- Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.Blood advances · 2023Article
- Expansion of mixed immune cells using CD3/CD161 co-stimulation for the treatment of cancer.Scientific reports · 2023Article
- Natural Killer T-like Cells: Immunobiology and Role in Disease.International journal of molecular sciences · 2023Review
- Innate adaptive immune cell dynamics in tonsillar tissues during chronic SIV infection.Frontiers in immunology · 2023Article
- Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma.Frontiers in immunology · 2023Review
- Dysfunction of circulating CD3International journal of medical sciences · 2023Article
- Circulating immunophenotypes are potentially prognostic in follicular cell-derived thyroid cancer.Frontiers in immunology · 2023Observational
- T-Cell Immune Imbalance in Rheumatoid Arthritis Is Associated with Alterations in NK Cells and NK-Like T Cells Expressing CD38.Journal of innate immunity · 2022Article
- Trained Immunity of IL-12-, IL-15-, and IL-18-Induced CDJournal of oncology · 2022Article
- Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapy with Tyrosine Kinase Inhibitors (TKI) aiming stable deep molecular response is the gold standard to treat Chronic Myeloid Leukemia (CML). NKT-like cells (CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.